← All trials
NCT05172037
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 28, 2021
- Primary completion
- Mar 31, 2022
- Completion date
- Jun 30, 2022
- First posted
- Dec 29, 2021
- Last posted
- Mar 3, 2022
- Enrollment
- 222
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beijing Genova Biotech Company, Ltd.Lead sponsor
- Government of JapanCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.